Diffusion Pharmaceuticals Inc. (DFFN) has seen some recent volatility in the market and its stock closed at $0.5019 yesterday. People are starting to take notice of DFFN as the stock traded as high as $0.5515 and as low as $0.4750 in the prior market day.

Diffusion Pharmaceuticals Inc. (DFFN) average trading volume is 4.52M. However, in the prior market day Diffusion Pharmaceuticals Inc. (DFFN) traded 0 shares. The first downside support level on DFFN is $0.45 and the first upside resistance level on DFFN is $0.77. DFFN fifty day moving average is $0.3789 and DFFN two hundred day moving average is $0.5102.

Diffusion Pharmaceuticals Inc. (DFFN) most recent performance has been specified by the recent movement in DFFN stock. DFFN has performed 72.55% over the past 4 weeks, DFFN has performed 21.06% over the past 90 days and DFFN has shown -82.16% over the past 365 days. Diffusion Pharmaceuticals Inc. (DFFN) has a 12 month range of $0.2100 to $6.4900. Diffusion Pharmaceuticals Inc. (DFFN) is trading 145.17% from its 12 month low and -92.03% from its 12 month high. Diffusion Pharmaceuticals Inc. (DFFN) is showing a 0.74% short float showing the sum short in the float.

DFFN has 35.58M shares outstanding and 34.51M shares in the float. Diffusion Pharmaceuticals Inc. (DFFN) at this time has a market cap of $18.41M and income of $-11.80M. The EPS next quarter for DFFN is -0.09 and anticipated EPS net year is 30.60%. The market cap of Diffusion Pharmaceuticals Inc. (DFFN) at $18.41M signifies how many People own shares of DFFN and is calculated off the last price ($0.5019) of DFFN and the sum of shares outstanding (35.58M) with Diffusion Pharmaceuticals Inc. (DFFN).

Diffusion Pharmaceuticals Inc. (DFFN) has total cash (mrq) of 14.18M, total cash per share (mrq) of 0.41, total debt of DFFN rests at 247.04k and total debt/equity (mrq) is 1.23. Diffusion Pharmaceuticals Inc. (DFFN) running cash flow (ttm) is -9.86M and DFFN leveraged free cash flow (ttm) is -5.35M.

DFFN is trading 18.28% above (bullish) its SMA20, 34.30% above (bullish) its SMA50 and -48.78% below (bearish) its SMA200.

Recent Diffusion Pharmaceuticals Inc. (DFFN) News:

In recent news, on April 29, 2020, it was announced, First quarter 2020 GDP: U.S. economy contracted for the first time in six years. In this news it stated, U.S. gross domestic product turned negative for the first time since 2014 in the first three months of the year as the coronavirus pandemic broadened out across the globe and country in March, dragging output to a near standstill and driving a deep contraction in consumer spending. The U.S. Bureau of Economic Analysis (BEA) released its advance estimate of first-quarter 2020 GDP Wednesday morning. Here were the main metrics from the report, compared to consensus expectations compiled by Bloomberg:

About Diffusion Pharmaceuticals Inc. (DFFN):

Diffusion Pharmaceuticals Inc. is a biotechnology company. Its product pipeline includes Trans Sodium Crocetinate, Glioblastoma Program, Pancreatic Cancer Program and Brain Metastases Program.